Sonnet biotherapeutics announces 1-for-14 reverse stock split

Princeton, nj / accesswire / september 16, 2022 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a 1-for-14 reverse stock split of its outstanding common stock. this will be effective for trading purposes as of the commencement of trading on monday, september 19, 2022.
SONN Ratings Summary
SONN Quant Ranking